- Researchers investigated whether the SSPOP gene, previously labeled a non-functional pseudogene (a DNA sequence resembling a gene), contributes to epilepsy.
- The study used trio-based whole exome sequencing to identify genetic variants in four children from three unrelated families.
- Researchers identified compound heterozygous variants (two different mutations in one gene) in SSPOP across four patients with seizures.
- Analysis of ten brain tissue samples and zebrafish models confirmed that SSPOP is a functional gene regulating neural development.
- Clinicians should consider SSPOP mutations as a potential genetic etiology for patients presenting with unexplained epilepsy and neurodevelopmental disorders.
Expanding the Genetic Map of Pediatric Epilepsy
Neurodevelopmental disorders and epilepsy represent a significant global health burden, affecting over 3.4 billion individuals and often presenting with complex, overlapping phenotypes [1]. While next-generation sequencing has improved diagnostic yields for these conditions compared to traditional chromosomal microarrays, approximately two-thirds of patients still remain without a definitive molecular diagnosis [2]. Identifying the specific genetic drivers of these disorders is essential for refining prognosis, guiding antiseizure medication selection, and providing accurate family counseling [3, 4]. The genetic architecture of epilepsy is highly heterogeneous, involving a mix of common risk loci and rare, highly penetrant monogenic variants [5]. A recent study offers fresh insights into how previously overlooked segments of the human genome may contribute to these challenging clinical presentations, potentially expanding the diagnostic toolkit for pediatric neurologists.
Clinical Presentation of SSPOP-Related Disorders
To identify the genetic drivers behind unexplained neurodevelopmental delay, the researchers utilized trio-based whole exome sequencing (a diagnostic method that sequences the protein-coding regions of a child and both biological parents to pinpoint inherited or spontaneous mutations). This analysis identified compound heterozygous SSPOP variants in four children, meaning each child possessed two different mutations in the same gene, with one variant inherited from each parent. These four patients originated from three unrelated families, and the cohort notably included one pair of dizygotic twins who both carried the pathogenic variants. By identifying these specific genetic markers, the study establishes a direct link between SSPOP mutations and a distinct clinical profile that had previously eluded molecular diagnosis.
The clinical presentation among the four children was characterized by significant phenotypic variability, particularly regarding their epilepsy. The researchers observed a wide variation in the age of seizure onset and diverse seizure semiology (the specific clinical signs and symptoms observed during a seizure event). Furthermore, the patients demonstrated variable responses to antiseizure medications, with some children showing better seizure control than others on standard therapeutic regimens. Beyond their epilepsy, all four children presented with concomitant neurodevelopmental disorders, highlighting that SSPOP mutations contribute to a complex spectrum of neurological impairment rather than isolated seizure activity. For practicing physicians, these findings suggest that SSPOP variants should be considered when evaluating patients with heterogeneous neurodevelopmental delays and difficult-to-manage epilepsy, as identifying these mutations could eventually guide more tailored therapeutic strategies.
Reclassifying a Pseudogene as a Functional Driver
The central discovery of this study involves the reclassification of the SSPOP gene, which is currently categorized in the human genome as a pseudogene (a genomic sequence that resembles a functional gene but is generally considered non-functional DNA). The researchers demonstrated that SSPOP is actually a functional gene that encodes the SCO-spondin protein. While the precise mechanisms of SCO-spondin remain poorly understood, it is known to play an important role in human neurodevelopment. To confirm that SSPOP is biologically active, the team verified its expression at both the transcriptional level and the protein level using a rigorous suite of laboratory techniques. These included quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure gene expression, immunofluorescence to visualize protein localization, and western blotting to detect specific protein molecules.
To validate these findings in human tissue, the researchers analyzed 10 brain tissue samples obtained from seven pediatric patients. They further utilized brain organoids (three-dimensional tissue cultures derived from human induced pluripotent stem cells that mimic the complex structure of the developing brain). The data from these models confirmed that SSPOP maintains a consistent biological function during both the pre-natal and post-natal stages of brain development. By proving that this supposed pseudogene is actively expressed in the developing and mature brain, the study provides a molecular basis for how its mutation leads to the seizure activity and developmental delays observed in the clinical cohort. This evidence suggests that SSPOP should be integrated into diagnostic genetic panels for pediatric neurological disorders, allowing clinicians to offer definitive answers to families who previously received inconclusive genetic testing results.
In Vivo Evidence of Epileptogenesis
To validate the pathogenicity of the identified variants in a living system, the researchers employed CRISPR-mediated sspo knockout zebrafish (an animal model where the zebrafish equivalent of the human SSPOP gene was intentionally deactivated using gene-editing technology). This in vivo approach allowed the team to move beyond cellular observations and assess the systemic impact of gene loss on a developing vertebrate nervous system. The use of zebrafish is particularly relevant in this context due to their high degree of genetic conservation with humans and the ability to monitor neural activity in real time during early development.
The results of the gene deactivation were definitive. The sspo knockout zebrafish demonstrated abnormal neurodevelopment, providing physical evidence that the gene is essential for proper brain formation and structural integrity. More critically for the clinical context of the study, these models also demonstrated epileptic discharges, which were captured through electrophysiological monitoring. These objective discharges in the zebrafish brain mirror the seizure activity observed in the pediatric patients, establishing a direct link between the loss of SSPOP function and the development of hyperexcitable neural circuits.
Based on the convergence of human genetic data, protein expression analysis, and animal modeling, the study suggests that SSPOP is a functional gene and a contributor to neurodevelopmental disorders and epilepsy. For the practicing clinician, these findings indicate that SSPOP should no longer be overlooked as a non-functional pseudogene. Instead, it should be considered a candidate gene in the diagnostic workup of patients presenting with unexplained developmental delay and seizure disorders. Identifying mutations in this gene may provide a definitive molecular diagnosis for families who have previously undergone inconclusive genetic testing, potentially refining the prognostic outlook and guiding long-term care for affected children.
References
1. Steinmetz JD, Seeher K, Schiess N, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology. 2024. doi:10.1016/s1474-4422(24)00038-3
2. Chang Y, Huang Y, Lai P. Genetic testing for diagnosing neurodevelopmental disorders and epilepsy: a systematic review and meta-analysis.. Systematic reviews. 2025. doi:10.1186/s13643-025-02896-y
3. Anastasescu CM, Gheorman V, Godeanu SV, et al. KIAA2022/NEXMIF c.1882C>T (p.Arg628*) Variant in a Romanian Patient with Neurodevelopmental Disorders and Epilepsy: A Case Report and Systematic Review.. Life (Basel, Switzerland). 2025. doi:10.3390/life15030497
4. Marotta N, Boland MJ, Prosser BL. Accelerating therapeutic development and clinical trial readiness for STXBP1 and SYNGAP1 disorders.. Current problems in pediatric and adolescent health care. 2024. doi:10.1016/j.cppeds.2024.101576
5. Stevelink R, Campbell C, Chen S, et al. GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. Nature Genetics. 2023. doi:10.1038/s41588-023-01485-w